MedTrace Logo

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

NCT03033355 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2025-08-05

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to evaluate higher neural changes following intra-detrusor injection of Onabotulinumtoxin-A (BTX-A) in patients with Multiple Sclerosis (MS).

We will use our prospectively collected cohort of patients. Concurrent Urodynamic and Functional Magnetic Resonance (fMRI) data will be recorded pre- and post-intravesical injection of BTX-A in patients with Multiple Sclerosis (MS) and neurogenic detrusor activity (NDO).

Conditions

  • Multiple Sclerosis
  • Lower Urinary Tract Symptoms
  • Neurogenic Bladder
  • Detrusor, Overactive
  • Urge Incontinence

Interventions

DRUG

Intra-detrusor injection of Onabotulinumtoxin-A

Using cystoscopy, Onabotulinumtoxin-A is injected into the bladder.

Sponsors & Collaborators

  • The Methodist Hospital Research Institute

    lead OTHER

Principal Investigators

  • Rose Khavari, MD · The Methodist Hospital Research Institute

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2019-03-31
Completion
2019-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03033355 on ClinicalTrials.gov